ArticleThe American journal of tropical medicine and hygiene2022
Pfs47 as a Malaria Transmission-Blocking Vaccine Target.
Article in The American journal of tropical medicine and hygiene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- The transmission-blocking dynamics of Plasmodium falciparum sexual-stage antibody responses in a six-year cohort of Ugandan children and adults.Nature communications · 2026Article
- Disruption of the AgMOBP1-PfSyn5 interface abolishes malaria transmission.bioRxiv : the preprint server for biology · 2026Article
- The kinetics and transmission-blocking dynamics ofResearch square · 2026Article
- Worldwide genetic diversity of Plasmodium vivax Pv47 is consistent with natural selection by anopheline mosquitoes.Nature communications · 2025Article
- Mosquito immune responses to Plasmodium parasites that limit malaria transmission.Cellular and molecular life sciences : CMLS · 2025Review
- Advances in the dissection of Anopheles-Plasmodium interactions.PLoS pathogens · 2025Review
- Controlled human malaria infection: overview and potential application in the evaluation of transmission-blocking interventions in malaria-endemic areas.Malaria journal · 2025Review
- Multi-locus investigation of Anopheles-mediated selective pressure on Plasmodium falciparum in Africa.Parasites & vectors · 2024Article
- Multi-locus investigation of Anopheles-mediated selective pressure on Plasmodium falciparum in Africa.Research square · 2024Article
- Analysis of Complexome Profiles with the Gaussian Interaction Profiler (GIP) Reveals Novel Protein Complexes inJournal of proteome research · 2024Article
- Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in Plasmodium falciparum.EBioMedicine · 2024Article
- Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates inmedRxiv : the preprint server for health sciences · 2024Article
- Coevolutionary Analysis of the Pfs47-P47Rec Complex: A Bioinformatics Approach.Bioinformatics and biology insights · 2024Article
- Article
- PCR-RFLP assays for the identification of Anopheles (Diptera: Culicidae) species circulating in Honduras.Malaria journal · 2023Article
- Transmission-Blocking Vaccines: From Conceptualization to Realization.The American journal of tropical medicine and hygiene · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Transmission-blocking vaccines (TBVs), pioneered by Richard Carter and others, aim to prevent parasite development in the mosquito vector and are a promising new tool for malaria elimination. Pfs47, recently identified as a TBV target, is a three-domain 6-cysteine protein on the surface of Plasmodium falciparum sexual stages. Pfs47 allows the parasite to evade mosquito immunity and is key for P. falciparum infection of the dominant malaria vectors Anopheles gambiae, Anopheles dirus, and Anopheles albimanus. Antibodies against Pfs47 domain 2 (D2) have significant transmission-blocking activity that prevents Plasmodium ookinete development and is independent of human complement. Strong transmission-blocking activity has been mapped to a region of 52 amino acids in Pfs47 D2. Efforts to optimize the immunogenicity of the Pfs47 D2 antigen with a viral-like particle have been successful, and the efficacy of a P47-based TBV was confirmed in vivo with Pbs47, the orthologue of Pfs47 in the mouse malaria parasite Plasmodium berghei. The current evidence warrants further development and clinical testing of a Pfs47-based TBV.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.